Search

AB Science SA

Uždarymo kaina

1.386 2.21

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.332

Max

1.44

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.4M

Pardavimai

512K

Pelno marža

-656.641

Darbuotojai

28

EBITDA

-1.9M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+264.69% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-10-13

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

85M

Ankstesnė atidarymo kaina

-0.82

Ankstesnė uždarymo kaina

1.386

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-10-07 16:58; UTC

Uždarbis

BMW Trims 2025 View, Citing Weaker Performance in China

2025-10-07 23:43; UTC

Rinkos pokalbiai

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

2025-10-07 23:36; UTC

Rinkos pokalbiai

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

2025-10-07 23:19; UTC

Rinkos pokalbiai

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 22:50; UTC

Rinkos pokalbiai

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

2025-10-07 22:40; UTC

Rinkos pokalbiai

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2025-10-07 21:56; UTC

Rinkos pokalbiai

Australia Shares Set to Start Day Roughly Flat -- Market Talk

2025-10-07 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 20:44; UTC

Karštos akcijos

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

2025-10-07 19:42; UTC

Rinkos pokalbiai

Treasury Yields Fall as Data Blackout Continues -- Market Talk

2025-10-07 19:23; UTC

Įsigijimai, susijungimai, perėmimai

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

2025-10-07 19:07; UTC

Rinkos pokalbiai

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

2025-10-07 19:02; UTC

Rinkos pokalbiai

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Tech, Media & Telecom Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2025-10-07 16:20; UTC

Rinkos pokalbiai

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

2025-10-07 16:15; UTC

Rinkos pokalbiai

Global Commodities Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 15:37; UTC

Rinkos pokalbiai

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

2025-10-07 15:33; UTC

Rinkos pokalbiai

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

2025-10-07 15:25; UTC

Rinkos pokalbiai

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

2025-10-07 15:15; UTC

Rinkos pokalbiai

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

2025-10-07 15:04; UTC

Rinkos pokalbiai

Market Talk Roundup: Latest on U.S. Politics

2025-10-07 15:04; UTC

Rinkos pokalbiai

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-10-07 14:56; UTC

Rinkos pokalbiai

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

2025-10-07 14:52; UTC

Uždarbis

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

AB Science SA Prognozė

Kainos tikslas

By TipRanks

264.69% į viršų

12 mėnesių prognozė

Vidutinis 5.033 EUR  264.69%

Aukščiausias 5.032 EUR

Žemiausias 5.032 EUR

Remiantis 1 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines AB Science SA kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

1 ratings

1

Pirkti

0

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
help-icon Live chat